Mergers & Acquisitions
SenzaGen Closes Alcyomics Deal at £2.1 Million Upfront With £1.9 Million in Earn-Outs
By News Desk ·
Key takeaways
- SenzaGen completed its acquisition of all Alcyomics shares at an initial price of approximately £2.1 million.
- The upfront consideration was funded by cash and SEK 25.0 million in convertible bonds, with earn-outs of up to approximately £1.9 million possible.
- Alcyomics reported FY2025/26 revenue of about SEK 19.5 million and an EBITDA margin of roughly 24%.
SenzaGen has completed its acquisition of all Alcyomics shares at an initial price of approximately £2.1 million, funded by cash and SEK 25.0 million in convertible bonds, with earn-outs of up to approximately £1.9 million possibly payable. TradingView reported the completion on November 5, 2026.
SenzaGen is a Swedish biotech founded in 2010 in Lund that provides animal-free, genomics-based immunotoxicological testing of chemical compounds to cosmetics, pharmaceutical and chemical manufacturers. Alcyomics is a UK-based provider of non-animal immunotoxicology solutions for drug development.
How the Alcyomics Deal Is Structured
The initial price of approximately £2.1 million was funded by cash and SEK 25.0 million in convertible bonds, according to the announcement. Earn-outs of up to approximately £1.9 million may be payable on top of that upfront amount.
Alcyomics reported FY2025/26 revenue of about SEK 19.5 million and an EBITDA margin of roughly 24%. SenzaGen said the acquisition adds a business focused on non-animal immunotoxicology testing, and Alcyomics is consolidated from the completion date.
TradingView reported on November 5, 2026 that SenzaGen's third-quarter revenue grew 7% with positive EBITDA and EBIT, and that the Alcyomics purchase adds a profitable pharma-testing business and broadens its growth opportunity.
SenzaGen's Funding and Leadership Record
SenzaGen's company records on akta.pro list one funding round: a grant of $2.6 million in March 2017, described as approximately $2.55 million in non-dilutive grant funding from the European Innovation Council and SMEs Executive Agency (EISMEA). The same records list Peter Nählstedt as President and Chief Executive Officer, Anki Malmborg as Chief Executive Officer and Malin Lindstedt as founder.
Earlier Steps Toward the Alcyomics Purchase
On October 28, 2026, TradingView reported that SenzaGen agreed to acquire Alcyomics for approximately SEK 28 million, financed by cash and SEK 25 million in convertible bonds. On November 2, 2026, TradingView reported that SenzaGen's subsidiary VitroScreen secured a SEK 2.8 million order from an existing global health and beauty ingredients supplier for non-animal efficacy studies, with testing starting immediately.
On August 20, 2026, Investing.com reported that SenzaGen posted a 13% year-over-year increase in second-quarter revenue to SEK 15.3 million, driven by a turnaround at VitroScreen.